Additionally, we conducted Western blot analyses to assess HDAC6 expression and the inhibitory effects of BKS-112 across a diverse panel of cancer cell lines, including A549 (lung cancer), DU145 (prostate cancer), Caki-1 (renal cell carcinoma), SKOV3 (ovarian cancer), MDA-MB-231 (TNBC), and MCF-7 (ER-positive breast cancer), as shown in Supplementary Figure S4a,b. Here, HDAC6 is linked to ovarian carcinoma.